Behind the blinding white light of Monday’s trillion–dollar AI wipeout that was a spot of unabashedly good AI news.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The pandemic saw a flurry of investment in biotech startups but the past three years have seen shrinking investments in the sector.
By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals’ dominance in the GLP-1 space.
Modifi Biosciences announced that it has been acquired by global pharmaceutical giant Merck, with a $30 million down payment.
Neuralink wants to protect implants from interference.
Moderna says it was willing to licence the tech but now wants to be repaid by rivals for vaccine revenue generated since then.
Bioprospecting for genes of new species in the world’s oceans has become complex and extremely lucrative.
The company’s stock ran higher after the company buoyed investors’ hopes that its technology will boost a lineup of new popular drugs.
The growing sector scored its second-highest month ever for total money-raising.
Some of pharma’s biggest players — including Merck, Amgen, Abbvie, and Gilead — formed an alliance to fight looming M&A reforms.